Livmarli Shows Long-Term Efficacy in Relieving Itch for Adolescents with Alagille Syndrome

New clinical trial data analysis reveals sustained efficacy of Livmarli (maralixibat) in treating cholestasis-related itching among adolescents with Alagille syndrome, offering hope for long-term symptom management in this rare genetic disorder.

Researchers from the University of Toronto, in collaboration with Mirum Pharmaceuticals, analyzed data from 14 adolescents with Alagille syndrome who participated in various clinical trials, including the Phase 2 studies ITCH, IMAGO, and their extension trials. The median treatment duration was 4.1 years, providing valuable insights into the long-term effectiveness of the therapy.

Significant Improvement in Itch Severity

Among the eleven patients who began Livmarli treatment before age 16, the median Itch-Reported Outcome (Observer) score decreased dramatically from 2.4 points at baseline to 0.6 points after treatment initiation. This reduction, indicating a shift from substantial itching to minimal or no itching, was maintained throughout the treatment period.

The three patients who started treatment after age 16 also experienced improvements, with one patient showing a notable reduction of 2.8 points in their itch score. The remaining two patients demonstrated more modest improvements of one point or less.

Mechanism of Action and Clinical Impact

Livmarli works by preventing bile reabsorption in the intestines, thereby increasing its excretion and reducing blood levels. This mechanism directly addresses the underlying cause of cholestasis-related itching in Alagille syndrome, a condition characterized by impaired bile flow from the liver.

The therapy is currently approved in the United States for patients 3 months and older, and in Europe for patients as young as 2 months old. Laboratory tests confirmed the clinical benefits, showing significant and sustained reductions in blood bile acid levels following treatment initiation.

Safety Profile and Study Limitations

The treatment demonstrated a favorable safety profile, with no serious medication-related adverse events reported. The most common side effects were mild and included diarrhea and abdominal pain.

The researchers acknowledged study limitations, notably the small patient population and the inclusion of participants with relatively minimal liver disease. This may limit the generalizability of results to patients with more advanced hepatic complications.

Despite these limitations, the findings suggest that Livmarli could significantly benefit Alagille syndrome patients who retain their native livers into adulthood, offering a promising long-term treatment option for this challenging condition.